{"entity":{"id":"enb-therapeutics","kind":"company","name":"ENB Therapeutics","aka":["ENB Therapeutics, Inc."],"tldr":"ENB Therapeutics is a New York biotech that blocks the endothelin B receptor, a switch tumours use to shut out immune cells, so that checkpoint inhibitors work in melanoma and other cancers that had stopped responding.","summary":"ENB Therapeutics develops ENB-003, a selective endothelin B receptor antagonist. Endothelin B signalling in the tumour vasculature and on tumour cells blocks T-cell infiltration and supports immune evasion; ENB-003 is designed to reverse this. It has been tested with pembrolizumab in a phase 1/2 study in advanced melanoma, ovarian cancer and other solid tumours that had progressed on checkpoint inhibitors.","asOf":"2026-09-17","links":[],"tags":["drug-maker"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["enb003"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo drug-maker linking round (corporate websites and regulatory records)","editedOn":"2026-09-17"},"hq":"New York, New York","country":"US","companyType":"biotech","investors":[],"funding":[]},"route":"/companies/enb-therapeutics/","neighbours":{"drug":[{"id":"enb003","kind":"drug","name":"ENB003","route":"/drugs/enb003/"}]}}